Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
SEARCH · Engineering Papers
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.
As part of the Cyclotron Road program, HOPO Therapeutics investigated the technical capabilities of heavy metal chelating agents for the sequestration, (re)distribution, delivery, and removal of metal ions, and their applications in the health, environment, and energy sectors. The project team researched chelating agents for use in the removal of heavy metals, and evaluated their potential benefits for a range of therapeutic, environmental, and energy applications.
A comprehensive ab initio study of periodic actinide–ligand bonding trends for trivalent actinides is performed. Relativistic density functional theory (DFT) and complete active-space (CAS) self-consistent field wavefunction calculations are used to dissect the chemical bonding in the [AnCl 6 ] 3– , [An(CN) 6 ] 3– , [An(NCS) 6 ] 3– , [An(S 2 PMe 2 ) 3 ], [An(DPA) 3 ] 3– , and [An(HOPO)] – series of actinide (An = U–Es) complexes. Except for some differences for the early actinide complexes with DPA, bond orders and excess 5f-shell populations from donation bonding show qualitatively similar trends in 5f n active-space CAS vs DFT calculations. The influence of spin–orbit coupling on donation bonding is small for the tested systems. Along the actinide series, chemically soft vs chemically harder ligands exhibit clear differences in bonding trends. There are pronounced changes in the 5f populations when moving from Pu to Am or Cm, which correlate with previously noted “breaks” in chemical trends. As a result, bonding involving 5f becomes very weak beyond Cm/Bk. We propose that Cm(III) is a borderline case among the trivalent actinides that can be meaningfully considered to be involved in ground-state 5f covalent bonding.
3,4,3-LI(1,2-HOPO) can be used as a HPLC chelating agent, promoting lanthanide and trivalent actinide separation without column modifications.
227 Th is a promising radioisotope for targeted α-particle therapy. It produces 5 α-particles through its decay, with the clinically approved 223 Ra as its first daughter. There is an ample supply of 227 Th, allowing for clinical use; however, the chemical challenges of chelating this large tetravalent f-block cation are considerable. Using the CD20-targeting antibody ofatumumab, we evaluated chelation of 227 Th 4+ for α-particle–emitting and radiotheranostic applications. Methods: We compared 4 bifunctional chelators for thorium radiopharmaceutical preparation: S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), 2-(4-isothicyanatobenzyl)-1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid (p-SCN-Bn-HEHA), p-isothiacyanatophenyl-1-hydroxy-2-oxopiperidine-desferrioxamine (DFOcyclo*-p-Phe-NCS), and macrocyclic 1,2-HOPO N-hydroxysuccinimide (L804-NHS). Immunoconstructs were evaluated for yield, purity, and stability in vitro and in vivo. Tumor targeting of the lead 227 Th-labeled compound in vivo was performed in CD20-expressing models and compared with a companion 89 Zr-labeled PET agent. Results: 227 Th-labeled ofatumumab-chelator constructs were synthesized to a radiochemical purity of more than 95%, excepting HEHA. 227 Th-HEHA-ofatumumab showed moderate in vitro stability. 227 Th-DFOcyclo*-ofatumumab presented excellent 227 Th labeling efficiency; however, high liver and spleen uptake was revealed in vivo, indicative of aggregation. 227 Th-DOTA-ofatumumab labeled poorly, yielding no more than 5%, with low specific activity (0.08 GBq/g) and modest long-term in vitro stability (<80%). 227 Th-L804-ofatumumab coordinated 227 Th rapidly and efficiently at high yields, purity, and specific activity (8 GBq/g) and demonstrated extended stability. In vivo tumor targeting confirmed the utility of this chelator, and the diagnostic analog, 89 Zr-L804-ofatumumab, showed organ distribution matching that of 227 Th to delineate SU-DHL-6 tumors. Conclusion: Commercially available and novel chelators for 227 Th showed a range of performances. The L804 chelator can be used with potent radiotheranostic capabilities for 89 Zr/ 227 Th quantitative imaging and α-particle therapy.
This report details spectroscopic characterizations of rare-earth, core-shell nanoparticles decorated with the f -element chelator 3,4,3-LI(1,2-HOPO). Evidence of photon downconversion is corroborated through detailed power dependence measurements, which suggest two-photon decay paths are active in these materials, albeit only representing a minority contribution of the sum luminescence, with emission being dominated by normal, Stokes' shifted fluorescence. Specifically, ultraviolet ligand photosensitization of Nd 3+ ions in a NaGdF 4 host shell results in energy transfer to a Nd 3+ /Yb 3+ -doped NaGdF 4 nanoparticle core. The population and subsequent decay of core, Yb 3+ 2 F 5/2 states result in a spectral shift of 620 nm, manifested in a NIR emission displaying luminescence profiles diagnostic of Yb 3+ and Nd 3+ excited state decays. Emphasis is placed on the generality of this material architecture for realizing ligand-pumped, multi-photon downconversion, with the Nd 3+ /Yb 3+ system presented here functioning as a working prototype for a design principle that may be readily extended to other lanthanide pairs.
An overview presentation for the Fundamental Radiation Chemistry component of the Material Recovery and Waste Form Development campaign to be delivered to the campaign team. The overview includes all major findings from FY19 research projects, current state of FY20 research projects, additional projects completed between FY19 and now, and finally our vision for the future direction of the Fundamental Radiation Chemistry component.